छोड़कर सामग्री पर जाएँ

Lupin shares gain on tentative USFDA approval for Valbenazine capsules

Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations.

Read More

​ Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations. Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी